Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for ... - MarketWatch (press release)
Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for ... MarketWatch (press release) Patients experienced a robust magnitude and duration of bronchodilation comparable to the active comparators, a rapid onset of action (approximately 5 minutes), and a fast treatment time of less than 3 minutes as delivered via the eFlow nebulizer.
Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for ... - PR Newswire (press release)
Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for ... PR Newswire (press release) Patients experienced a robust magnitude and duration of bronchodilation comparable to the active comparators, a rapid onset of action (approximately 5 minutes), and a fast treatment time of less than 3 minutes as delivered via the eFlow nebulizer.
Lung Disease Following Deployment in Iraq and Afghanistan news Stories 3 Subsequent epidemiologic studies showed that deployers have higher rates of newly reported respiratory symptoms than nondeployers (14% versus 10%), although rates of physician-diagnosed asthma and chronic bronchitis were not increased.
Targeted Therapies in the Management of Leukemia and Lymphoma - Cancer Network
Targeted Therapies in the Management of Leukemia and Lymphoma Cancer Network [2] The reported response rate was 48%, with 6% complete responses (CRs) and a median duration of response of about 1 year. Subsequent studies confirmed its effectiveness as a single agent in both the upfront and refractory disease settings.
Sunovion Announces Upcoming Availability of ZETONNA(TM) (ciclesonide) Nasal ... MarketWatch (press release) ... cough, influenza, bronchitis, streptococcal pharyngitis, muscle strain, and nausea. Nasal discomfort (5.7%) and epistaxis (11.4%) were also more frequent in the 26 week trial compared to clinical trials 2 to 6 weeks in duration.
